利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.053 秒)

    Rate control during AF using cellular intervention to modulate AV node
    5.
    发明授权
    Rate control during AF using cellular intervention to modulate AV node 有权
    使用细胞干预调整AV节点的AF期间的速率控制

    公开(公告)号：US08565898B2

    公开(公告)日：2013-10-22

    申请号：US11116621

    申请日：2005-04-28

    申请人： Vinod Sharma ,  Daniel C. Sigg

    发明人： Vinod Sharma ,  Daniel C. Sigg

    IPC分类号： A61N1/00 ,  A61K38/00 ,  A61K38/16

    CPC分类号： A61N1/362 ,  A61K9/0019 ,  A61K31/221 ,  A61K38/177 ,  A61N1/0568

    摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.

    摘要翻译： 生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。 具体地，通用代理用于调制心脏传导系统中的节点，包括使用一个K +通道或等效物系的组合的速率控制。 具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。 例如，可以使用Kv1.3通道作为生物通道。 本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。

    PRESSURE MONITORING TO CONTROL DELIVERY OF THERAPEUTIC AGENT
    6.
    发明申请
    PRESSURE MONITORING TO CONTROL DELIVERY OF THERAPEUTIC AGENT 有权
    压力监测控制治疗药物的输送

    公开(公告)号：US20100274221A1

    公开(公告)日：2010-10-28

    申请号：US12767224

    申请日：2010-04-26

    申请人： Daniel C. Sigg ,  Prasanga D. Hiniduma-Lokuge ,  Mary M. Morris

    发明人： Daniel C. Sigg ,  Prasanga D. Hiniduma-Lokuge ,  Mary M. Morris

    IPC分类号： A61M5/172 ,  A61B5/03

    CPC分类号： A61B5/036 ,  A61B5/0031 ,  A61B5/0215 ,  A61B5/4839 ,  A61M5/14276 ,  A61M5/16854 ,  A61M5/1723 ,  A61M2005/1726 ,  A61M2205/3331 ,  A61M2205/3334

    摘要： A method for adjusting delivery of a therapeutic fluid to a patient suffering from or at risk of pulmonary arterial hypertension includes introducing the therapeutic fluid to a patient via a catheter at a predetermined rate. The catheter is positioned to deliver the fluid to the right ventricle or the pulmonary artery. The catheter a one-way valve configured to allow the fluid to flow from the catheter to the target location. The method further includes monitoring pressure of the target location by monitoring internal catheter pressure, and adjusting the rate at which the therapeutic fluid is introduced to the catheter based on the monitored pressure. The rate at which the fluid is introduced to the catheter is increased if internal catheter pressure increases, and the rate at which the fluid is introduced to the catheter is decreased if the internal catheter pressure decreases.

    摘要翻译： 用于调节对患有或具有肺动脉高压的风险的患者的治疗流体的递送的方法包括以预定的速率经由导管将治疗流体引入患者体内。 定位导管以将流体输送到右心室或肺动脉。 导管是单向阀，其构造成允许流体从导管流到目标位置。 该方法还包括通过监测内部导管压力来监测目标位置的压力，并且基于所监测的压力来调节治疗流体被引入导管的速率。 如果内部导管压力增加，流体被引入导管的速率增加，并且如果内部导管压力降低，则将流体引入导管的速率降低。

    METHODS AND SYSTEMS FOR PROVIDING THERAPIES INTO THE PERICARDIAL SPACE
    8.
    发明申请
    METHODS AND SYSTEMS FOR PROVIDING THERAPIES INTO THE PERICARDIAL SPACE 有权
    将治疗提供给心脏空间的方法和系统

    公开(公告)号：US20120035587A1

    公开(公告)日：2012-02-09

    申请号：US13273521

    申请日：2011-10-14

    申请人： Daniel C. Sigg ,  Michael R. Ujhelyi ,  Mary M. Morris

    发明人： Daniel C. Sigg ,  Michael R. Ujhelyi ,  Mary M. Morris

    IPC分类号： A61M5/168 ,  A61M5/142

    CPC分类号： A61M5/14276 ,  A61B17/00234 ,  A61B17/3417 ,  A61B17/3478 ,  A61B18/1492 ,  A61B2017/00247 ,  A61B2017/003 ,  A61B2017/22077 ,  A61B2017/3484 ,  A61B2017/3488 ,  A61B2017/349 ,  A61B2018/00291 ,  A61B2018/00357 ,  A61B2018/00392 ,  A61M5/1723 ,  A61M2005/1405 ,  A61M2205/3523

    摘要： Methods and systems for transvenously accessing the pericardial space via the vascular system and atrial wall, particularly through the superior vena cava and right atrial wall, to deliver a pharmacologic agent, particularly a NO-donor drug, to the heart are disclosed. A proximal connector of an infusion catheter is coupled to an infusion pump, and a distal catheter segment having a distal infusion catheter lumen end opening is disposed in the pericardial space. The implantable infusion pump is operable in conjunction with an implantable ischemia monitor to monitor the ischemic state and trigger delivery or regulate the periodic delivery of the pharmacologic agent to optimally treat ischemia. The patient may operate a patient activator that the patient when feeling ischemia symptoms to transmit a signal that is received by the implantable infusion pump and triggers delivery of a bolus and/or continuous infusion.

    摘要翻译： 公开了通过血管系统和心房壁，特别是通过上腔静脉和右心房壁经心脏进入心包空间的方法和系统，以向心脏递送药理学特别是NO供体药物。 输注导管的近端连接器联接到输注泵，并且具有远端输注导管腔端部开口的远侧导管段设置在心包空间中。 可植入输注泵可与可植入缺血监测器结合操作以监测缺血状态并触发递送或调节药理学剂的周期性递送以最佳地治疗缺血。 患者可以操作患者活化剂，当感觉到缺血症状时患者传递由可植入输液泵接收的信号并触发推注和/或连续输注的传递。

    Delivery of a sympatholytic cardiovascular agent to the central nervous system
    9.
    发明授权
    Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
    交配性心血管药物向中枢神经系统递送

    公开(公告)号：US07390311B2

    公开(公告)日：2008-06-24

    申请号：US10903599

    申请日：2004-07-30

    申请人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    发明人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    IPC分类号： A61M31/00

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和 右美托咪定）。

    Delivery of a sympatholytic cardiovascular agent to the central nervous system
    10.
    发明授权
    Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
    交配性心血管药物向中枢神经系统递送

    公开(公告)号：US08348884B2

    公开(公告)日：2013-01-08

    申请号：US12128046

    申请日：2008-05-28

    申请人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    发明人： Keith R. Hildebrand ,  Michael R. Ujhelyi ,  Xiaohong Zhou ,  Daniel C. Sigg ,  Linda M. Page

    IPC分类号： A61M31/00

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和 右美托咪定）。